Retina Synthesis

Retina Synthesis

Education EN ↓ 207 episodi

Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.

Visita il sito del podcast e sostieni chi lo crea: retinasynthesis.com

Autore

Retina Synthesis

Categoria

Education

Sito del podcast

retinasynthesis.com

Ultimo episodio

17 nov 2026

Dove ascoltare?

I podcast nell'app Replaio Radio In arrivo

I podcast stanno per arrivare nell'app. Installala ora e scopri per primo un modo tutto nuovo di vivere i podcast

Scaricala su Google Play Installala gratis Android 10 mln+ di download · valutazione 4,7+ iOS in arrivo

Episodi

Vamikibart at One Year: MEERKAT and SANDCAT in Uveitic Macular Edema 17.11.2026

Nisha Acharya joins Carmen Puliafito to discuss the MEERKAT and SANDCAT Phase 3 trials of vamikibart, an intravitreal anti–IL-6 antibody for uveitic macular edema. She walks through the week-16 primary endpoint — met at both doses in MEERKAT, while in SANDCAT the 1 mg arm missed and the 0.25 mg result stands as nominally significant — the striking durability after just four monthly doses, the larg...

PRIMA at 36 Months: Durable Vision Gains and Long-Term Safety in Geographic Atrophy 14.11.2026

Ehsan Rahimy joins Carmen Puliafito to discuss the PRIMA photovoltaic retinal implant for advanced geographic atrophy. In PRIMAvera, average prosthetic acuity gains grew from about 25 letters at 12 months to about 30 at 36 months, and 84 percent of patients could read letters and words at home. Rahimy reviews the 36-month safety record — most events clustered in the first six months, with no chron...

Use of Anti-VEGF Agents Before and After Non-Ophthalmic Incisional Surgery 10.11.2026

Use of anti-VEGF agents in the perioperative period in patients undergoing non-ophthalmic incisional surgery was not associated with increased surgical complications. Our guest is Dr. Odette Houghton of the Mayo Clinic, Scottsdale, Arizona.

GLOW2: Tarcocimab Delivers Six-Month Durability in Diabetic Retinopathy 07.11.2026

Margaret A. Chang, MD, MS, Senior Partner at Retinal Consultants Medical Group in Sacramento, joins hosts Carmen Puliafito and Charles Wykoff to discuss GLOW2, Kodiak's second Phase 3 trial of tarcocimab in diabetic retinopathy. Using the enhanced formulation — 4 mg antibody-biopolymer conjugate plus 1 mg free antibody — GLOW2 enrolled moderately severe to severe NPDR plus mild PDR and mild D...

ELAAVATE: First Subretinal Gene Therapy for Diabetic Macular Edema 03.11.2026

Dr. Arshad M. Khanani, Managing Partner and Director of Clinical Research at Sierra Eye Associates, discusses ELAAVATE, his investigator-sponsored Phase 2 trial of subretinal surabgene lomparvovec (sura-vec) — the first subretinal gene therapy tested in center-involved diabetic macular edema. In nine surgeries, treatment burden fell 70.5% at the low dose and 79.1% at the high dose, with vision mai...

PRISM at Two Years: The Eye as Biofactory 30.10.2026

Carl Danzig discusses two-year results from PRISM, the Phase 1/2 trial of 4D-150, a single in-office intravitreal gene therapy that turns the retina into a biofactory producing aflibercept and blocking VEGF-C. In recently diagnosed patients, vision and retinal thickness were maintained, 66% needed no supplemental injections over two years, and the group averaged just 1.6 supplemental injections. D...

Bevacizumab Passes Eylea: How Copay Assistance Rewired Retina Practice 27.10.2026

Anton Kolomeyer walks through Vestrum Health data on intravitreal injection use from 2023 to 2025, presented at ASRS 2026. Bevacizumab climbed to about 30 percent of injections in 2025, passing aflibercept 2 milligrams, which fell from nearly 46 percent, as the loss of Good Days copay assistance left Medicare Advantage patients unable to afford branded drugs. He covers the growth of faricimab, afl...

Gene Therapy for Geographic Atrophy: 12-Month ArMaDa Results 19.10.2026

Help Shape What’s Next on Retina Synthesis Tell us what you enjoy and what you’d like to hear more of. Our listener survey is anonymous and takes under 3 minutes. Your feedback will help guide future episodes. Take the survey: https://docs.google.com/forms/d/e/1FAIpQLSfPvwGmK_zEzF7x5f7bBM78nCsYLyS6Ga3jrJMAHg2FmvtLng/viewform Thank you for being part of the Retina Synthesis community! Dr. Raj Matur...

Preserving Vision, Not Just Slowing the Lesion: ARCHER II and Vonaprument 13.10.2026

Dr. Ashkan Abbey, Director of Clinical Research at Texas Retina Associates, returns to discuss vonaprument (ANX007), a C1q inhibitor that blocks complement upstream of C3 and C5. In Phase 2 ARCHER, monthly treatment cut the risk of ≥15-letter vision loss by about 73% and preserved photoreceptors on OCT, while lesion growth on autofluorescence did not change. He explains the Phase 3 ARCHER II desig...

The Drop That Dried the Macula but Missed on Vision: DIAMOND-1/2 and OCS-01 08.10.2026

Can a drop replace the needle in diabetic macular edema? Dr. Veeral Sheth returns to Retina Synthesis to walk through DIAMOND-1 and DIAMOND-2, Oculis's twin Phase 3 trials of OCS-01, a high-concentration (15 mg/mL) topical dexamethasone formulated to reach the posterior segment. Across 800+ patients with mild-to-moderate DME, the drop did what it was supposed to do anatomically — central thic...

Combined Anti-IL 6 and Anti-VEGF Therapy for Diabetic Macular Edema 01.10.2026

We welcome back Dr. Roger Goldberg from Bay Area Retina Associates, in our latest episode to discuss the BARDENAS trial (NCT05151744) a global Phase 2 clinical study evaluating the efficacy and safety of vamikibart (RO7200220), an IL-6 inhibitor, combined with ranibizumab for treating diabetic macular edema (DME). 

Surgery for Encapsulated Cell Therapy 23.09.2026

In this episode, we discuss the surgical technique and complications associated with implantation of an encapsulated cell therapy for MacTel 2 with Dr. Lloyd Clark from North Carolina Retina Association.

Results of the Eyepoint LUGANO Trial 16.09.2026

In this episode, we discuss the results of the Phase 3 Lugano Trial from Eyepoint Pharmaceuticals with Dr. Carl Regillo of Wills Eye Hospital.

A Subcutaneous TKI for the Treatment of Neovascular AMD and Diabetic Retinopathy 09.09.2026

In this episode we discuss the use of  a subcutaneously administered tyrosine  kinase inhibitor migaldendranib (D-4517.2)  or MGB for the treatment of neovascular AMD and diabetic macular edema with Dr. Michael Singer from San Antonio

Gene Therapy for Inherited Retinal Degenerations 02.09.2026

In this episode, we review the current status of gene therapy for inherited retinal degenerations with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute

Faricimab Therapy for Polypoidal Choroidal Vasculopathy (PCV) 26.08.2026

In this episode, we discuss the latest developments in faricimab therapy of polypoidal choroidal vasculopathy, with Dr. Gemmy Cheung, Head of the Medical Retina Division, at the Singapore National Eye Center.

The ASRS ReST Commitee 19.08.2026

In this episode, we review the work of the Research in Safety and Therapeutics (ReST)Committee of the American Society of Retinal Specialists (ASRS) with Dr. Andre Witkin, Chair of the ReST Committee, and Professor of Ophthalmology at Tufts University School of Medicine, New England Eye Center, and Ophthalmic Consultants of Boston.

The Therapeutic Pipeline for Geographic Atrophy in AMD 12.08.2026

In this episode, we discuss potential new treatments for geographic atrophy of age related macular degeneration with Dr. Jessica Randolph of Wagner Kapoor Institute in Richmond, Virginia.

Hand Held Office Based ERG for Evaluating Diabetic Retinopathy 04.08.2026

In this episode, we discuss the use of handheld ERG in the evaluating eye with diabetic retinopathy. ERG is a powerful predictive tool in assessing diabetic retinopathy. Our guest is Dr. Raj Maturi of the Midwest Eye Institute and Adjunct Associate Professor of Ophthalmology, at the Indiana University School of Medicine.

4 Year Outcomes of Faricimab Therapy of Neovascular AMD 30.07.2026

In this episode, we discuss the long term results of faricimab therapy of neovascular AMD with Dr. Carl Danzig of Fort Lauderdale, Florida and Affiliate Assistant Professor at the Charles Schmidt School of Medicine at Florida Atlantic University.

5 Year Results of Pegacetacoplan Treatment of Geographic Atrophy 21.07.2026

In this episode, we discuss 5 year results of the GALE study which demonstrated that earlier treatment with pegcetacoplan of geographic atrophy preserves more retinal tissue with Dr. Dilsher Dhoot, California Retina Consultants, Adjunct Clinical Assistant Professor Ophthalmology, Roski Eye Institute, Keck School of Medicine of USC.

Polychoroidal Vasculopathy (PCV) 15.07.2026

In this episode, we discuss the importance of early recognition of PCV, diagnostic techniques, and therapeutic approaches with Professor Jay Chhablani of the University of Pittsburgh.

AREDS Vitamins and Geographic Atrophy 07.07.2026

In this episode, we review the evidence regarding the effectiveness of AREDS vitamin supplementation in affecting the growth of geographic atrophy in age related macular degeneration.

Intravitreal Gene Therapy for Neovascular AMD with 4D-150 16.06.2026

In this episode, we discuss the promising results of intravitreal gene therapy for neovascular AMD with 4D-150 with Dr. Arshad Khanani of Sierra Eye Associates and Clinical Professor of Ophthalmology at the University of Nevada Medical School, Reno.

Home OCT in Management of Neovascular AMD 08.06.2026

In this episode, we discuss the latest developments in the use of artificial intelligence in home OCT for management of neovascular AMD with Professor Anat Loewenstein of Tel Aviv Medical Center and President, Israeli Ophthalmology Society.

Ascolta il podcast Retina Synthesis su Replaio

Radio e podcast in un'unica app - gratis e senza registrazione. Installala oggi e non perderti il lancio

Scaricala su Google Play

Replaio non è un editore di podcast; i nomi dei programmi, le copertine e l'audio appartengono ai rispettivi autori e vengono distribuiti tramite feed RSS pubblici